Study pharmacy admin of vaccines:

 Without having the time for the COD and the board to discuss this, I would be comfortable saying that any expansion of vaccination should not occur without an appropriate study of harms and benefits either retrospective including pneumococcal vaccination and Zostavax, or prospective pilot for any new vaccines.  My suspicion is that if pneumococcal vaccine were studied, we would find harm far outweighs benefit because of the problems associated with too frequent vaccination-which even if from a health standpoint were "harm neutral" is still harm by providing expensive unnecessary care. Important Public health policy should not be based on conjecture and assumptions; that is a very firm principal of our specialty and evidence-based medicine.